Anti-CD20 therapy in patients with refractory systemic lupus erythematosus: A longitudinal analysis of 52 Hispanic patients

Lupus

Volumn 19, Issue 2, 2010, Pages 213-219

  Garcia Carrasco, M ^a,b   Mendoza Pinto, C ^a   Sandoval Cruz, M ^a   Soto Vega, E ^a   Beltran Castillo, A ^a   Jimenez Hernandez, M ^a   Graillet, D ^a   Gonzalez, L ^a   Rojas Rodriguez, J ^a   Pineda Almazana, A ^a   Zamudio Huerta, L ^a   Lopez Colombo, A ^a  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b BENEMÉRITA UNIVERSIDAD AUTÓNOMA DE PUEBLA   (Mexico)

Author keywords

Refractory treatment; Rituximab; SLE

Indexed keywords

AZATHIOPRINE; CD20 ANTIBODY; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; IMMUNOSUPPRESSIVE AGENT; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARACETAMOL; PREDNISONE; RITUXIMAB;

ADULT; AGED; ARTHRALGIA; ARTHRITIS; ARTICLE; CONTROLLED STUDY; CYTOPENIA; DISEASE ACTIVITY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FEVER; HEMATURIA; HISPANIC; HUMAN; INFECTION; JOINT SWELLING; KIDNEY FAILURE; LEUKOPENIA; LONGITUDINAL STUDY; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; MEXICO; NEUTROPENIA; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; POLYARTHRITIS; PRIORITY JOURNAL; PROTEINURIA; RASH; REFRACTORY AUTOIMMUNE CYTOPENIA; REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS; REMISSION; SERUM SICKNESS; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE; VASCULITIS;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; LONGITUDINAL STUDIES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MEXICO; MIDDLE AGED; PREDNISONE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; YOUNG ADULT;

EID: 76049094173     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309351541     Document Type: Article

References (31)

1. Rahman A., Isenberg DA Systemic lupus erythematosus. N Engl J Med 2008 ; 358: 929-939.
2. Boumpas D., Austin HA III, Vaughan EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992 ; 340: 741-745.
3. Ding Ch, Foote S., Jones G. B cell targeted therapy for systemic lupus erythematosus. An update. Biodrugs 2008 ; 22: 239-249.
4. García-Carrasco M., Jiménez-Hernández M., Escárcega RO, et al. Use of rituximab in patients with systemic lupus erythematosus: an update. Autoimmun Rev 2009 ; 8: 343-348.
5. Anolik JH, Campbell D., Felgar RE, et al. The relationship of Fc gamma RIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003 ; 48: 455-459.
6. Leandro MJ, Cambridge G., Edwards JC, Ehrenstein MR, Isenberg DA B cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology 2005 ; 44: 1542-1545.
7. Smith KG, Jones RB, Burns SM, Jayne DR Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: remission, relapse, and retreatment. Arthritis Rheum 2006 ; 54: 2970-2982.
8. Tokunaga M., Saito K., Kawabata D., et al. Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007 ; 66: 470-475.
9. Vigna-Perez M., Hernandez-Castro B., Paredes-Saharopulos O., et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006 ; 8: R83.
10. Leandro MJ, Edwards JC, Cambridge G., Ehrenstein MR, Isenberg DA An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002 ; 46: 2673-2677.
11. Ng KP, Cambridge G., Leandro MJ, Edwards JC, Ehrenstein N., Isenberg DA B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of response. Ann Rheum Dis 2007 ; 66: 1259-1262.
12. Gunnarsson I., Sundelin B., Jónsdóttir T., Jacobson SH, Henriksson EW, van Vollenhoven RF Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide resistant proliferative lupus nephritis. Arthritis Rheum 2007 ; 56: 1263-1272.
13. Tamimoto Y., Horiuchi T., Tsukamoto H., et al. A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans? syndrome: immunological analysis of B cells, T cells and cytokines. Rheumatology 2008 ; 47: 821-827.
14. Lindholm C., Borjesson-Asp K., Zendjanchi K., Sundqvist AC, Tarkowski A., Bokarewa M. Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systematic lupus erythematosus. J Rheumatol 2008 ; 35: 826-833.
15. Camous L., Melander C., Vallet M., et al. Complete remission of lupus nephritis with rituximab and steroids for induction and rituximab alone for maintenance therapy. Am J Kidney Dis 2008 ; 52: 346-352.
16. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF The 1982 revised criteria of the classification of systemic lupus erythematosus. Arthritis Rheum 1982 ; 25: 1271-1277.
17. Hochberg MC Updating the American College of Rheumatology revised classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997 ; 40: 1725.
18. Guzman J., Cardiel MH, Arce-Salinas A., Sanchez-Guerrero J., Alarcon-Segovia D. Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatology 1992 ; 19: 1551-1558.
19. Sfikakis PP, Boletis JN, Lionaki S., et al. Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: an open-label trial. Arthritis Rheum 2005 ; 52: 501-513.
20. Galarza C., Valencia D., Tobón GJ, et al. Should rituximab be considered as the first-choice treatment for 484 severe autoimmune rheumatic diseases? Clin Rev Allergy Immunol 485 2008 ; 34: 124-128.
21. Rivera TL, Belmont HM, Malani S., et al. Current therapies for lupus nephritis in an ethnically heterogeneous cohort. J Rheumatol 2009 ; 36: 298-305.
22. Contreras G., Pardo V., Leclercq B., et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004 ; 350: 971-980.
23. Contreras G., Lenz O., Pardo V., et al. Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int 2006 ; 69: 1846-1851.
24. Merill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in patients with moderately to severely active systemic lupus erythematosus (SLE): results from the randomized, double-blind phase II/III study EXPLORER (abstract L12). Presented at the American College of Rheumatology Annual Meeting, 2008 October 24-29, San Francisco, CA.
25. Phase III Study of Rituxan in Lupus Nephritis Did Not Meet Primary Endpoint (online) www.gene.com/gene/news/press-releases/display.do?method= detail&id=11947&categoryid=4 ( 2009 ).
26. Shanafelt TD, Madueme HL, Wolf RC, Tefferi A. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome. May Clin Proc 2003 ; 78: 1340-1346.
27. Braendstrup P., Bjerrum OW, Nielsen OJ, et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura. Am J Hematol 2005 ; 78: 275-280.
28. Kneitz C., Wilhelm M., Tony HP Effective B cell depletion with rituximab in the treatment of autoimmune diseases. Immunobiology 2002 ; 206: 519-527.
29. van Vugt RM, Derksen RH, Kater L., Bijlsma JW Deforming arthropathy or lupus and rhupus hands in systemic lupus erythematosus. Ann Rheum Dis 1998 ; 57: 540-544.
30. Aringer M., Graninger WB, Steiner G., Smolen JS Safety and efficacy of tumor necrosis α blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004 ; 50: 3161-3169.
31. Uppal S., Hayat S., Raghopathy R. Efficacy and safety of infliximab in active SLE: a pilot study. Lupus 2009 ; 18: 690-697.